Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Re-challenge with Panitumumab and Chemotherapy in Metastatic Colorectal Cancer (REPAN)
NCT03940131Phase 2Unknown
- Sponsor
- King Abdullah Medical City
- Start
- Jun 2020
- Primary completion
- Jul 2022
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of panitumumab in metastatic colorectal cancer (mCRC), sponsored by King Abdullah Medical City. Primary endpoint: Overall Response Rate at 3 years. Status: unknown.
02
Drugs
panitumumab
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT03940131.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03940131.